CNS Drugs

, Volume 28, Issue 10, pp 963–973

Atypical Antipsychotics Olanzapine, Quetiapine, and Risperidone and Risk of Acute Major Cardiovascular Events in Young and Middle-Aged Adults: A Nationwide Register-Based Cohort Study in Denmark

  • Björn Pasternak
  • Henrik Svanström
  • Mattis F. Ranthe
  • Mads Melbye
  • Anders Hviid
Original Research Article

DOI: 10.1007/s40263-014-0176-0

Cite this article as:
Pasternak, B., Svanström, H., Ranthe, M.F. et al. CNS Drugs (2014) 28: 963. doi:10.1007/s40263-014-0176-0

Abstract

Background

A number of serious cardiovascular safety concerns related to the use of atypical antipsychotics, compared with no use, have emerged, but nearly all reports are from studies of older patients. We aimed to compare the risk of cardiovascular events between the three most commonly used atypical antipsychotics in young and middle-aged adults.

Methods

We conducted a nationwide register-based cohort study in Denmark, 1997–2011, including adults aged 18–64 years, who started treatment with oral or intramuscular olanzapine (n = 15,774), oral quetiapine (n = 18,717), and oral or intramuscular risperidone (n = 14,134). The primary outcome was any major cardiovascular event (composite of cardiovascular mortality, acute coronary syndrome, or ischemic stroke) within 1 year following treatment initiation. Cox regression was used to estimate hazard ratios (HRs) while on current antipsychotic monotherapy in the outpatient setting, adjusting for an outcome-specific disease risk score.

Results

The crude rate of any major cardiovascular event was 5.3 per 1,000 person-years among olanzapine users, 3.4 in quetiapine users, and 5.2 in risperidone users. Compared with risperidone, the risk of any major cardiovascular event was not significantly different in olanzapine users (HR 0.90, 95 % confidence interval [CI] 0.53–1.52) and quetiapine users (HR 0.79, 95 % CI 0.45–1.39). The absolute risk difference per 1,000 person-years on treatment was −0.5 (95 % CI −2.4 to 2.7) events for olanzapine and −1.1 (95 % CI −2.9 to 2.0) events for quetiapine.

Conclusions

Among young and middle-aged outpatients, the risk of acute major cardiovascular events was similar with use of olanzapine, quetiapine, and risperidone. Although moderate relative differences cannot be ruled out, any differences are small in absolute terms.

Supplementary material

40263_2014_176_MOESM1_ESM.pdf (55 kb)
Supplementary material 1 (PDF 55 kb)

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Björn Pasternak
    • 1
  • Henrik Svanström
    • 1
  • Mattis F. Ranthe
    • 1
  • Mads Melbye
    • 1
    • 2
  • Anders Hviid
    • 1
  1. 1.Department of Epidemiology ResearchStatens Serum InstitutCopenhagen SDenmark
  2. 2.Department of MedicineStanford School of MedicineStanfordUSA